In Jung Kim, Geun Joo Choi, Hyoung-Chul Oh, Hyun Kang
{"title":"雷马唑仑和异丙酚在内镜逆行胆管造影中镇静作用的比较：系统评价和荟萃分析与试验序列分析。","authors":"In Jung Kim, Geun Joo Choi, Hyoung-Chul Oh, Hyun Kang","doi":"10.1111/den.15078","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Sedation for endoscopic retrograde cholangiopancreatography (ERCP) is challenging owing to patient comorbidities and procedural complexity. Remimazolam, a novel benzodiazepine, has potential safety benefits. We aimed to systematically compare the efficacy and safety of remimazolam and propofol for ERCP sedation through a meta-analysis and trial sequential analysis (TSA).</p><p><strong>Methods: </strong>We searched Ovid-MEDLINE, Ovid-Embase, Cochrane Central, and Google Scholar for randomized controlled trials (RCTs) that compared efficacy and safety of remimazolam and propofol in ERCP sedation. Sensitivity analysis and TSA were also performed.</p><p><strong>Results: </strong>Five RCTs (965 participants) were included. In these trials, remimazolam significantly reduced hypoxia (risk ratio [RR], 0.522; 95% confidence interval [CI] 0.348-0.783; Grading of Recommendations, Assessment, Development, and Evaluation [GRADE], high), hypotension (RR, 0.507; 95% CI 0.396-0.649; GRADE, high), and bradycardia (RR, 0.475; 95% CI 0.308-0.732; GRADE, high). However, it increased tachycardia (RR, 3.363; 95% CI, 1.466-7.714; GRADE, moderate) and body movement (RR, 2.744; 95% CI, 1.216-6.193; GRADE, moderate). Delirium and agitation (RR, 0.586; 95% CI, 0.157-2.179; GRADE, moderate) and completion rate (RR, 1.009; 95% CI, 0.97-1.042; GRADE, moderate) were comparable. Recovery quality was higher in remimazolam group (mean difference, 1.541; 95% CI, 0.057-3.024; GRADE, low). Other outcomes, including induction and recovery times, were similar.</p><p><strong>Conclusion: </strong>Remimazolam demonstrated superior safety profile than propofol for ERCP sedation, significantly reducing hypoxia, hypotension, and bradycardia with high certainty evidence and TSA confirmation. Despite the higher incidence of tachycardia and body movement associated with remimazolam, the completion rate and risk of delirium or agitation were similar for both sedatives.</p>","PeriodicalId":72813,"journal":{"name":"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Remimazolam and Propofol for Sedation in Endoscopic Retrograde Cholangiopancreatography: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.\",\"authors\":\"In Jung Kim, Geun Joo Choi, Hyoung-Chul Oh, Hyun Kang\",\"doi\":\"10.1111/den.15078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Sedation for endoscopic retrograde cholangiopancreatography (ERCP) is challenging owing to patient comorbidities and procedural complexity. Remimazolam, a novel benzodiazepine, has potential safety benefits. We aimed to systematically compare the efficacy and safety of remimazolam and propofol for ERCP sedation through a meta-analysis and trial sequential analysis (TSA).</p><p><strong>Methods: </strong>We searched Ovid-MEDLINE, Ovid-Embase, Cochrane Central, and Google Scholar for randomized controlled trials (RCTs) that compared efficacy and safety of remimazolam and propofol in ERCP sedation. Sensitivity analysis and TSA were also performed.</p><p><strong>Results: </strong>Five RCTs (965 participants) were included. In these trials, remimazolam significantly reduced hypoxia (risk ratio [RR], 0.522; 95% confidence interval [CI] 0.348-0.783; Grading of Recommendations, Assessment, Development, and Evaluation [GRADE], high), hypotension (RR, 0.507; 95% CI 0.396-0.649; GRADE, high), and bradycardia (RR, 0.475; 95% CI 0.308-0.732; GRADE, high). However, it increased tachycardia (RR, 3.363; 95% CI, 1.466-7.714; GRADE, moderate) and body movement (RR, 2.744; 95% CI, 1.216-6.193; GRADE, moderate). Delirium and agitation (RR, 0.586; 95% CI, 0.157-2.179; GRADE, moderate) and completion rate (RR, 1.009; 95% CI, 0.97-1.042; GRADE, moderate) were comparable. Recovery quality was higher in remimazolam group (mean difference, 1.541; 95% CI, 0.057-3.024; GRADE, low). Other outcomes, including induction and recovery times, were similar.</p><p><strong>Conclusion: </strong>Remimazolam demonstrated superior safety profile than propofol for ERCP sedation, significantly reducing hypoxia, hypotension, and bradycardia with high certainty evidence and TSA confirmation. Despite the higher incidence of tachycardia and body movement associated with remimazolam, the completion rate and risk of delirium or agitation were similar for both sedatives.</p>\",\"PeriodicalId\":72813,\"journal\":{\"name\":\"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/den.15078\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/den.15078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparison of Remimazolam and Propofol for Sedation in Endoscopic Retrograde Cholangiopancreatography: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.
Objectives: Sedation for endoscopic retrograde cholangiopancreatography (ERCP) is challenging owing to patient comorbidities and procedural complexity. Remimazolam, a novel benzodiazepine, has potential safety benefits. We aimed to systematically compare the efficacy and safety of remimazolam and propofol for ERCP sedation through a meta-analysis and trial sequential analysis (TSA).
Methods: We searched Ovid-MEDLINE, Ovid-Embase, Cochrane Central, and Google Scholar for randomized controlled trials (RCTs) that compared efficacy and safety of remimazolam and propofol in ERCP sedation. Sensitivity analysis and TSA were also performed.
Results: Five RCTs (965 participants) were included. In these trials, remimazolam significantly reduced hypoxia (risk ratio [RR], 0.522; 95% confidence interval [CI] 0.348-0.783; Grading of Recommendations, Assessment, Development, and Evaluation [GRADE], high), hypotension (RR, 0.507; 95% CI 0.396-0.649; GRADE, high), and bradycardia (RR, 0.475; 95% CI 0.308-0.732; GRADE, high). However, it increased tachycardia (RR, 3.363; 95% CI, 1.466-7.714; GRADE, moderate) and body movement (RR, 2.744; 95% CI, 1.216-6.193; GRADE, moderate). Delirium and agitation (RR, 0.586; 95% CI, 0.157-2.179; GRADE, moderate) and completion rate (RR, 1.009; 95% CI, 0.97-1.042; GRADE, moderate) were comparable. Recovery quality was higher in remimazolam group (mean difference, 1.541; 95% CI, 0.057-3.024; GRADE, low). Other outcomes, including induction and recovery times, were similar.
Conclusion: Remimazolam demonstrated superior safety profile than propofol for ERCP sedation, significantly reducing hypoxia, hypotension, and bradycardia with high certainty evidence and TSA confirmation. Despite the higher incidence of tachycardia and body movement associated with remimazolam, the completion rate and risk of delirium or agitation were similar for both sedatives.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
